

## CURRICULUM VITAE

Andrzej Pilc

### Personal Information

#### *Affiliation:*

Head of Neurobiology Department; Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Smętna 12 Str, Poland.

Head of Drug Management Department, Faculty of Public Health, Collegium Medicum Jagiellonian University, Krakow, Poland

### Education

**December 1987;** D.Sc., Department of Medicine, Medical Academy of Lodz, Poland., Thesis Title “The role of  $\alpha_2$ -adrenoceptors in the mechanism of action of antidepressant drugs”.

**October 1978.** Ph.D., Department of Medicine, Medical Academy of Lodz, Poland.

Thesis Title “ The role of histamine in thermoregulation” Supervisor Prof. C. Maslinski

**September 1972** M.D. Department of Medicine, Medical Academy of Lodz, Poland

### Active Funding as a principal investigator - recent 5 years

**2011-2014.** Program ERA-NET-NEURON /04/2011 “**Pharmacogenomics of Antidepressant Drug Response** (PADRE): tentative drug response biomarkers from human lymphoblastoid cells” Level of founding: approx. 140.000Euro.

**2010-2014.** POIG Program Depression, mechanisms, therapy DeMeTer, Leader of task 3.7 The level of financing approx 700.000 Eur.

**2009-2013.** POIG 1.1.3. Allosteric modulation – a new strategy in pharmacotherapy.

Identification of psychotropic properties of ligands of metabotropic group III mGlu receptors” Level of founding: approx. 2 million Euro

**2010-2011** Polish-Norwegian Research „Creating an academia based platform to discover substances acting on serotonergic or glutamatergic systems as potential new antidepressant or anxiolytic drugs” No - 103 - A I - 1/07, acronym: NOR-POL-MOOD. Level of founding: 1.640.324,00 Euro

**2006-2009** Polfarma Foundation to promote the development of Polish Pharmacy and Medicine. “Antidepressant effects of group III GPCR’s ligands and their role in the mechanism of action of antidepressant drugs”. Level of founding: approx. 110.000,00 Euro.

### Research interests

Depression/anxiety/schizophrenia and the mechanism of action of antidepressant/anxiolytic/antipsychotic drugs; Metabotropic receptors for excitatory amino acids and GABA; Involvement of group III GPCR’s in neuropsychiatric disorders.

### Key Words

- Animal behaviour
- Animal models
- Antidepressants: basic
- Anxiety
- Amino Acids
- GABA
- Glutamate
- Neuropharmacology
- Schizophrenia: Basic